戊乙奎醚对胸腔镜肺癌根治术患者术后恶心呕吐的影响:单中心、前瞻性、随机对照临床试验研究方案
本研究为单中心、前瞻性、双盲、随机对照临床试验,拟纳入446例胸腔镜肺癌根治术患者,按1:1随机分为试验组与对照组各223例。试验组麻醉前静脉注射戊乙奎醚0.25 mg并于术后48小时内静脉输注戊乙奎醚0.25 mg,对照组给予生理盐水。主要结局为术后24小时内恶心呕吐发生率,次要结局包括不同时间段恶心呕吐发生率与严重程度、术后48小时外科医生与患者满意度及不良反应。
要点
- 试验组麻醉前静脉注射戊乙奎醚0.25 mg,术后48小时内再静脉输注0.25 mg。
- 主要结局为术后24小时内恶心呕吐发生率,采用意向性分析。
- 次要结局含术后0-6、6-12、12-24小时恶心呕吐及术后48小时满意度与不良反应。
核心结论
- 作者假设静脉给予戊乙奎醚可降低胸腔镜肺癌根治术后恶心呕吐的发生率与严重程度,并提高外科医生与患者满意度。
研究设计与样本
- 单中心、前瞻性、双盲、随机对照临床试验,拟纳入446例择期行胸腔镜肺癌根治术的患者,按1:1随机分为试验组与对照组各223例。
- 试验组麻醉前静脉注射戊乙奎醚0.25 mg,术后48小时内静脉输注戊乙奎醚0.25 mg;对照组以生理盐水替代戊乙奎醚。
- 主要结局为术后24小时内恶心呕吐发生率,采用意向性分析。
关键数值与推荐
- 主要结局为术后24小时内恶心呕吐发生率。
- 次要结局包括术后0-6、6-12、12-24小时恶心呕吐发生率与严重程度。
- 次要结局包括术后48小时外科医生与患者满意度,采用视觉模拟量表评分。
- 次要结局包括术后48小时内口干、头晕、面部潮红、皮肤干燥、尿潴留、谵妄及体温升高的发生情况。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative nausea and vomiting (PONV) is a common complication of surgical procedures, especially of radical thoracoscopic lung cancer surgery, and causes patient discomfort, delays recovery, and increases healthcare costs. Penehyclidine hydrochloride (PHC), a novel anticholinergic agent, can potentially reduce surgery- and anesthesia-related adverse reactions such as PONV, possibly because of its selective M1 and M3 muscarinic receptor antagonism. The aim of this study is to investigate the efficacy and safety of PHC in reducing the incidence and severity of PONV after radical thoracoscopic lung cancer surgery. METHODS: This single-center, prospective, double-blind, randomized controlled clinical trial will include 446 patients scheduled for radical thoracoscopic lung cancer surgery. Enrolled participants will be randomly assigned to a test or control group in a 1:1 ratio, with 223 patients in each group. The test group will receive an intravenous injection of 0.25 mg PHC before anesthesia and an intravenous infusion of 0.25 mg PHC within 48 h after surgery, whereas the control group will receive normal saline instead of PHC. The primary outcome will be the incidence of PONV within 24 h post-surgery. Secondary outcomes will include the incidence and severity of PONV within different time intervals (0-6, 6-12, and 12-24 h post-surgery); surgeon and patient satisfaction levels at 48 h post-surgery, rated using a visual analog scale; and the occurrence of dry mouth, dizziness, red face, dry skin, urinary retention, delirium, and hyperthermia within 48 h post-surgery. An intention-to-treat analysis will be performed. DISCUSSION: We hypothesize that administration of intravenous PHC can reduce the incidence and severity of PONV and improve surgeon and patient satisfaction. The findings of this trial could have important implications for improving patient outcomes and optimizing postoperative care for patients who undergo radical thoracoscopic lung cancer surgery. TRIAL REGISTRATION: This trial protocol was registered in the Chinese Clinical Trial Registry on April 19, 2024 (registration number: ChiCTR2400083262).
引用
- Wang N, Hou SH, Meng R, et al. Effects of penehyclidine hydrochloride on postoperative nausea and vomiting in patients who underwent radical thoracoscopic lung cancer surgery: study protocol for a single-center, prospective, randomized controlled clinical trial. Trials. 2025. PMID: 41402907. doi:10.1186/s13063-025-09372-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。